Gareth Morgan
@DrGarethMorgan1
Clinician and researcher; committed to improving outcomes of myeloma, amyloid and Waldenstrom's.
Keeping up with rapidly evolving diagnostic and research based genomic testing in myeloma, excellent insights into best approaches being taken worldwide at #IMS #genomictesting
Super work from two excellent NYU resident @nyulangone
Moving Towards the Delivery of Outpatient T-Cell Engaging Therapy for the Management of Multiple Myeloma - ScienceDirect sciencedirect.com/science/articl…
Super work from two NYU residents #nyu #NYULangone
Moving Towards the Delivery of Outpatient T-Cell Engaging Therapy for the Management of Multiple Myeloma - ScienceDirect sciencedirect.com/science/articl…
Moving Towards the Delivery of Outpatient T-Cell Engaging Therapy for the Management of Multiple Myeloma - ScienceDirect sciencedirect.com/science/articl…
🚨: A 9,000-year-old skeleton in Somerset was genetically matched to a local man named Adrian Targett. Their mitochondrial DNA reveals an unbroken maternal lineage spanning 300 generations — the longest verified lineage in history.
Long-term outcomes of light chain amyloidosis patients receiving heart transplant: A single-center experience - PubMed pubmed.ncbi.nlm.nih.gov/40687315/
Welcoming Dr. John P. Leonard as chief of the Division of Hematology & Medical Oncology and director of the Center for Blood Cancers at @Perlmutter_CC! A global leader in lymphoma care, he brings decades of research and clinical expertise. Learn more: bit.ly/46eRupF
The beauty of mathematics resides in its patterns and symmetries.
Yes. Writing is not a second thing that happens after thinking. The act of writing is an act of thinking. Writing *is* thinking. Students, academics, and anyone else who outsources their writing to LLMs will find their screens full of words and their minds emptied of thought.
Good to see some good press from @TheEconomist on the impact of cancer basic+clinical research...#CancerResearch #Cancer
Good news often goes unreported, especially if it happens gradually. That is the story of the war on cancer. Death rates are down substantially—and are likely to fall further. Future gains will come from three main sources econ.st/459V9Ec
GSK provides update on US FDA advisory committee review of Blenrep (belantamab mafodotin-blmf) combinations for patients with relapsed/refractory multiple myeloma | GSK - interesting twist! gsk.com/en-gb/media/pr…
Another disappointment for #AL #amyloidosis #depleters: CARES didn’t meet its primary endpoint. What exactly was the prespecified subgroup that showed benefit? 🤔 Does this mean anything for #ATTR depleters? Time (and full data) will tell. reuters.com/business/healt…
1/11 Our study on subclonal immune evasion in non-small cell lung cancer has just been published in @Cancer_Cell cell.com/cancer-cell/fu…
AbbVie Pays Up to $1.9 Billion for Trispecific Antibody | Cancer Discovery News | American Association for Cancer Research aacrjournals.org/cdnews/news/25…
This pretty interesting
#Myeloma Paper of the Day: BCMA is a highly short-lived protein that undergoes K48-linked polyubiquitylation at plasma membrane & carfilzomib enhances the efficacy of BCMA-directed CAR T cells against both PI-sensitive and refractory myeloma cells: pubmed.ncbi.nlm.nih.gov/40638685/. #mmsm
#Myeloma Paper of the Day: US Myeloma Immunotx Consortium teclistamab data: 54% CRS (1.4% G≥3), 11% ICANS (2.2% G≥3), 42% infxns, 53% ≥PR, 45% ≥VGPR, PFS 5.8 mos, 12-mo OS 61%; BCMA CAR w/in 9 mos, hi dz/ferritin, lymphopenia reduce benefit: pubmed.ncbi.nlm.nih.gov/40629516/. #mmsm
A single shot that reprograms your DNA to lower cholesterol—permanently. No pills. No injections. No heart attacks. Eli Lilly just paid $1.3B for the company making it real. If it works, it won’t just treat heart disease—it could erase it from medicine altogether.🧵